For patients needing a bone marrow or stem cell transplant, successful treatment often depends on finding a viable transplant sample with the right amount of hematopoietic stem cells (HSCs) to rebuild the patient’s immune system.
USP volunteers help shape the future of drug manufacturing
Consistent quality. Greater access. They’re what patients deserve and what USP strives to ensure across the globe through the development of public quality standards.
The quality of medicine and how it’s delivered to patients is fundamental to treating illness and maintaining health. At USP, we help build a safety net across the drug industry and healthcare system to preserve the well-being of patients.
January 1 was more than just the start of a new year for USP in 2018. It was the implementation date of two new standards designed to safeguard the global drug supply from potentially toxic impurities – mercury, cadmium, arsenic, and lead, for example.
USP was founded nearly 200 years ago by eleven doctors who wanted to ensure that the nation had access to quality medicines. They put together the first pharmacopeia, a book of recipes for making tinctures, extracts, and other medicines.
By the year 2020, biopharmaceuticals are estimated to account for 50% of the most successful pharmaceutical products. (1)(2) Biologics, such as recombinant therapeutic proteins, vaccines, blood components, and regenerative medicines are growing faster than any other segment of medicines.
Highly complex biologics such as proteins, monoclonal antibodies, and cell and gene therapies increasingly fill biopharmaceutical pipelines across a range of therapeutic indications.
Building the marketplace for generic medicines is a key strategy to containing drug costs in the US, one that USP actively supports through our standards-setting work.